[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nu Eyne Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054204","evaluation-of-an-electric-stimulator-for-medical-use-by-personal-lrtpm1-for-visual-function-in-early-to-intermediate-dry-age-related-macular-degeneration-100054204",false,"NCT07700147","Evaluation of an Electric Stimulator for Medical Use by Personal (LRTPM1) for Visual Function in Early to Intermediate Dry Age-Related Macular Degeneration","A Multicenter, Randomized, Double-Blind, Sham-Controlled, Parallel-Group Exploratory Clinical Trial Evaluating the Efficacy and Safety of an Electric Stimulator for Medical Use by Personal (LRTPM1) in Improving Visual Function in Patients With Early to Intermediate Dry Age-Related Macular Degeneration","Inclusion Criteria:\n\n1. Participants aged 50 years or older\n2. Participants diagnosed with early or intermediate dry age-related macular degeneration\n3. Participants with best corrected visual acuity measured by the ETDRS visual acuity chart of 20\u002F200 or better and 20\u002F30 or worse\n4. Participants who have voluntarily decided to participate in the study and have provided written informed consent.\n\nExclusion Criteria:\n\n1. Participants with atrophy involving the foveal center with a diameter of 175 micrometers or greater in at least one eye, as observed by fundus examination or fundus autofluorescence imaging\n2. Participants with exudative age-related macular degeneration in at least one eye, as observed by fundus examination or optical coherence tomography (OCT)\n3. Participants with a history of intraocular injection therapy or macular laser treatment, including focal laser photocoagulation or photodynamic therapy\n4. Participants with retinal or choroidal diseases other than early or intermediate age-related macular degeneration that may affect the study results, including diabetic retinopathy, retinal artery occlusion, retinal vein occlusion, central serous chorioretinopathy, optic neuritis, or uveitis\n5. Participants who have undergone vitrectomy due to retinal disease, or cataract surgery within 1 month prior to screening\n6. Participants with ocular media opacity or other conditions that, in the investigator's opinion, may make ophthalmic imaging difficult to interpret, including cataract, vitreous opacity, or vitreous hemorrhage\n7. Participants with uncontrolled chronic systemic diseases, including diabetes mellitus or chronic kidney disease, or a history of malignancy, except for cases with no recurrence within the past 5 years and no history of chemotherapy\n8. Participants with autoimmune diseases, including Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, or Graves' disease\n9. Participants with severe hearing impairment, sensory abnormalities, or cognitive impairment that may make it difficult to properly perform the study procedures or recognize or report adverse events\n10. Participants who are hypersensitive to orbital nerve stimulation and are unable to receive treatment\n11. Participants with a history of drug or alcohol abuse\n12. Participants diagnosed with psychiatric disorders, including depression, schizophrenia, bipolar disorder, or dementia\n13. Participants who have participated in another clinical trial within 30 days prior to screening\n14. Participants who are considered to have other contraindications to use of the investigational medical device, including underlying cardiac disease, seizure-related disorders, implanted metal or electronic devices in the head or neck area including deep brain stimulators, unexplained pain, implanted or wearable pacemakers, or other conditions listed in the product precautions and contraindications. Dental implants are exempt.\n15. Participants who, in the opinion of the investigator, are deemed inappropriate for participation in the study\n16. Female participants of childbearing potential who do not agree to use medically accepted contraception during the study period. Medically accepted methods of contraception include condoms, oral contraceptives used consistently for at least 3 months, injectable or implantable contraceptives, or intrauterine devices.","ALL","50 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to evaluate the efficacy and safety of an electric stimulator for medical use by personal (LRTPM1) in patients with early to intermediate dry age-related macular degeneration.\n\nThe main questions this study aims to answer are:\n\n* Does the investigational device improve visual function, as assessed by best corrected visual acuity and contrast sensitivity?\n* What treatment-emergent adverse events occur during the study?\n\nParticipants will:\n\n* Be randomized to receive either active stimulation or sham stimulation\n* Apply the assigned investigational device at home once daily for 30 minutes over a 12-week treatment period\n* Visit the study site for eye examinations and safety assessments\n* Return for a follow-up visit 4 weeks after the end of treatment",[26,27],"Dry Age-Related Macular Degeneration","AMD",[29,30,31,32],"Neurostimulation","Electrical stimulation","ES","stimulation","NOT_YET_RECRUITING","2026-07-07",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":20},"2026-07-09",{"date":41,"type":20},"2028-04-17",{"name":43,"class":44},"Nu Eyne Co., Ltd.","INDUSTRY",3,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100599032","evaluation-of-a-physical-device-for-medical-use-adtpm-1-for-opioid-withdrawal-symptoms-100599032","NCT07079215","Evaluation of a Physical Device for Medical Use (ADTPM 1) for Opioid Withdrawal Symptoms","A Single Center, Double-Blind, Randomized, Sham-Controlled, Parallel Design, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of a Medical Device for the Treatment of Opioid Withdrawal Symptoms","Inclusion Criteria:\n\n1. Participants aged 19 to 80 years\n2. Participants currently dependent on opioids, whether prescribed or non-prescribed\n3. Participants who meet the criteria for opioid use disorder (OUD) according to DSM-5\n4. Participants with a Clinical Opiate Withdrawal Scale (COWS) score of 5 or higher\n5. Participants with a Numeric Rating Scale (NRS) pain score of less than 6\n6. Participants who have voluntarily decided to participate in the study and have provided written informed consent\n7. Participants who are willing to comply with the study protocol\n\nExclusion Criteria:\n\n1. Participants with any current uncontrolled or clinically significant medical condition\n2. Participants with a history of seizures or epilepsy\n3. Participants with a history of neurological disorders or traumatic brain injury\n4. Participants who have used long-acting opioids, such as methadone or buprenorphine, continuously for more than 5 days prior to screening\n5. Participants who have used methadone within 30 days prior to screening\n6. Participants who have used buprenorphine within 7 days prior to screening\n7. Participants with physiological dependence on alcohol or drugs other than opioids, tobacco, or marijuana\n8. Participants diagnosed with a major psychiatric disorder (psychosis, schizophrenia, or bipolar disorder)\n9. Participants who are currently hospitalized due to a recent suicide attempt or who are persistently expressing suicidal intent\n10. Participants with implanted devices such as a pacemaker, cochlear implant, or neurostimulator.\n11. Participants with abnormal ear anatomy or ear infections\n12. Participants diagnosed with renal or hepatic failure\n13. Participants who are currently undergoing chemotherapy (Exception: Participation may be allowed if the investigator determines that participation poses no medical safety concerns for the participant)\n14. Participants who are currently engaged in high-risk occupations (e.g., transportation workers, crane operators, heavy machinery operators, individuals working with sharp objects, or those requiring a high level of cognitive functioning)\n15. Participants with implanted metal or electronic devices in the head or neck area, including deep brain stimulators or pacemakers, as specified in the product precautions and contraindications (dental implants are exempt)\n16. Participants with cognitive impairment due to neurodevelopmental disorders (e.g., intellectual disability, developmental disorders, autism spectrum disorder) or neurodegenerative disorders (e.g., Alzheimer's disease, vascular dementia) that would make it difficult to undergo treatment with the investigational medical device\n17. Participants who are pregnant or breastfeeding\n18. Female participants of childbearing potential who do not agree to abstain from sexual intercourse or to use medically accepted contraception\\* during the study period.\n\n    \\*Medically accepted methods of contraception include: condoms, consistent oral contraceptive use (≥3 months use), injectables or implantable contraceptives, or intrauterine devices (IUDs).\n19. Participants who are currently participating in another clinical trial or who have participated in another clinical trial within 30 days prior to screening\n20. Participants who, in the opinion of the investigator, are deemed inappropriate for participation due to ethical concerns or potential impacts on study outcomes","19 Years","80 Years",{"count":56,"type":20},24,[23],"This study aims to evaluate the safety and efficacy of a physical device for medical use (ADTPM 1) applied to opioid withdrawal symptoms.",[60,61],"Opioid Withdrawal (Disorder)","Opioid Use Disorder",[63],"OUD","RECRUITING","2025-07-13",{"date":67,"type":37},"2025-07-22",{"date":69,"type":37},"2025-05-30",{"date":71,"type":20},"2026-04-06",{"name":43,"class":44},1,""]